Director Declaration Sale of Shares

Evolutec Group plc
                    ("Evolutec" or "the Company")

Pursuant to rule 17 of AIM Regulations (Schedule 5), Dr David Philip
Bloxham (Chairman) disclosed on 17 March 2008 that on the same date
he sold 33,036 Ordinary 10p Shares in Evolutec Group plc at a price
of 18p per share.  The beneficial owner of the shares was the David
Philip Bloxham SIPP.  After this transaction Dr Bloxham holds 103,472
Ordinary Shares in the Company.

17 April 2008

Evolutec is listed on the AIM market of the London Stock Exchange and
developed therapeutics originally isolated from the saliva of  ticks.
Following the unsuccessful outcome of Phase II clinical trials on its
lead clinical trail candidate, the Company licensed its  intellectual
property to third parties and is now focussing all its activities  on
the identification of  a single  investment opportunity.   This  will
take advantage  of  Evolutec's AIM  listing  and its  cash  and  cash
equivalent reserve.

Safe Harbour statement: this news release may contain forward-looking
statements that  reflect  the  current expectations  of  the  Company
regarding future events. Forward-looking statements involve risks and
uncertainties. Actual  events  could  differ  materially  from  those
projected herein  and depend  on a  number of  factors including  the
success of  the Company's  strategy,  the successful  integration  of
completed  mergers  and  acquisitions  and  achievement  of  expected
synergies from such transactions, and  the ability of the Company  to
identify and consummate suitable  strategic and business  combination
transactions.

---END OF MESSAGE---